AZBio Elects Snell & Wilmer Attorney Tony Caldwell to Board of Directors

PHOENIX - Dec. 27, 2022 - PRLog -- Snell & Wilmer is pleased to announce that Tony Caldwell (https://www.swlaw.com/people/anthony_caldwell) has been elected to the Arizona Bioindustry Association (https://www.azbio.org/) (AZBio (https://www.azbio.org/azbio-board-of-directors/tony-caldwell)) Board of Directors.

AZBio is committed to serving its members, both as organizations and as individuals, by providing access to the key resources, connections and information that support the growth of a thriving economic ecosystem for Arizona's Bioscience Industry. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefit people in Arizona and around the world.

"On behalf of the over 30 members of Snell & Wilmer's Life Sciences and Medical Technology Industry Group, I am excited to join the Board of Directors of AZBio," said Caldwell. "I am excited for this opportunity to support our life sciences clients and grow Arizona's life science community."

Caldwell's day-to-day practice focuses on corporate, technology and life sciences transactions and contracting matters, with an emphasis on licensing, manufacturing and supply chain, clinical trials, data use, cybersecurity, and mergers and acquisitions. Caldwell advises biotechnology, pharmaceutical, medical device and diagnostics companies with commercial contracting and clinical matters, and he is a member of the firm's Life Science and Medical Technology Industry Group. He has a comprehensive understanding of the legal needs of the life sciences industry, including its regulatory framework, risks and opportunities, rapidly changing technologies, and competitive landscape. He has extensive experience negotiating pre-clinical and clinical trial agreements, material transfer agreements, and domestic and international supply chain agreements. He has also represented several life sciences companies in connection with M&A transactions and IPOs.
2022 Tony Caldwell press release.pdf (d33scoy2rrx0xd.cloudfront.net) (https://d33scoy2rrx0xd.cloudfront.net/assets/pdf/news/202...)